Use of a von Frey device for evaluation of pharmacokinetics and pharmacodynamics of morphine after intravenous administration as an infusion or multiple doses in dogs

Butch KuKanich Department of Molecular Biomedical Sciences, Pharmacology and Comparative Pain Research Laboratories, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.
Present address is the Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506-5802.

Search for other papers by Butch KuKanich in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
B. Duncan X. Lascelles Department of Clinical Sciences, Pharmacology and Comparative Pain Research Laboratories, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by B. Duncan X. Lascelles in
Current site
Google Scholar
PubMed
Close
 BVSc, PhD
, and
Mark G. Papich Department of Molecular Biomedical Sciences, Pharmacology and Comparative Pain Research Laboratories, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Mark G. Papich in
Current site
Google Scholar
PubMed
Close
 DVM, MS

Abstract

Objective—To evaluate the pharmacokinetics and pharmacodynamics of morphine after IV administration as an infusion or multiple doses in dogs by use of a von Frey (vF) device.

Animals—6 dogs.

Procedure—In the first 2 crossover experiments of a 3-way crossover study, morphine or saline (0.9%) solution was administered via IV infusion. Loading doses and infusion rates were administered to attain targeted plasma concentrations of 10, 20, 30, and 40 ng/mL. In the third experiment, morphine (0.5 mg/kg) was administered IV every 2 hours for 3 doses. The vF thresholds were measured hourly for 8 hours. Plasma concentrations of morphine were measured by highpressure liquid chromatography.

Results—No significant changes in vF thresholds were observed during infusion of saline solution. The vF thresholds were significantly increased from 5 to 8 hours during the infusion phase, corresponding to targeted morphine plasma concentrations > 30 ng/mL and infusion rates ≥ 0.15 ± 0.02 mg/kg/h. The maximal effect (EMAX) was 78 ± 11% (percentage change from baseline), and the effective concentration to attain a 50% maximal response (EC50) was 29.5 ± 5.4 ng/mL. The vF thresholds were significantly increased from 1 to 7 hours during the multiple-dose phase; the EC50 and EMAX were 23.9 ± 4.7 ng/mL and 173 ± 58%, respectively. No significant differences in half-life, volume of distribution, or clearance between the first and last dose of morphine were detected.

Conclusions and Clinical Relevance—Morphine administered via IV infusion (0.15 ± 0.02 mg/kg/h) and multiple doses (0.5 mg/kg, IV, every 2 hours for 3 doses) maintained significant antinociception in dogs. (Am J Vet Res 2005;66:1968–1974)

Abstract

Objective—To evaluate the pharmacokinetics and pharmacodynamics of morphine after IV administration as an infusion or multiple doses in dogs by use of a von Frey (vF) device.

Animals—6 dogs.

Procedure—In the first 2 crossover experiments of a 3-way crossover study, morphine or saline (0.9%) solution was administered via IV infusion. Loading doses and infusion rates were administered to attain targeted plasma concentrations of 10, 20, 30, and 40 ng/mL. In the third experiment, morphine (0.5 mg/kg) was administered IV every 2 hours for 3 doses. The vF thresholds were measured hourly for 8 hours. Plasma concentrations of morphine were measured by highpressure liquid chromatography.

Results—No significant changes in vF thresholds were observed during infusion of saline solution. The vF thresholds were significantly increased from 5 to 8 hours during the infusion phase, corresponding to targeted morphine plasma concentrations > 30 ng/mL and infusion rates ≥ 0.15 ± 0.02 mg/kg/h. The maximal effect (EMAX) was 78 ± 11% (percentage change from baseline), and the effective concentration to attain a 50% maximal response (EC50) was 29.5 ± 5.4 ng/mL. The vF thresholds were significantly increased from 1 to 7 hours during the multiple-dose phase; the EC50 and EMAX were 23.9 ± 4.7 ng/mL and 173 ± 58%, respectively. No significant differences in half-life, volume of distribution, or clearance between the first and last dose of morphine were detected.

Conclusions and Clinical Relevance—Morphine administered via IV infusion (0.15 ± 0.02 mg/kg/h) and multiple doses (0.5 mg/kg, IV, every 2 hours for 3 doses) maintained significant antinociception in dogs. (Am J Vet Res 2005;66:1968–1974)

All Time Past Year Past 30 Days
Abstract Views 39 0 0
Full Text Views 992 702 273
PDF Downloads 220 94 4
Advertisement